A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Trial details
- Registry ID
- NCT06346067
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ERAS-254; LXH254
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | ERAS | Phase 3 | Active not recruiting | 2028-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |